This week marks the sixth anniversary of the date that Bob Kyle, Henry Duong, and I incorporated Advera Health Analytics. We started this journey with a mission to improve patient outcomes by making drug safety data more accessible and actionable. We spent the early years developing our technologies, building our data delivery platform, and subjecting our early methodologies to peer review. Two years ago we began to commercialize our enterprise data product and since then we’ve grown exponentially.
In the past two weeks AdverseEvents has been invited to share our drug safety analytics and insight on two different panel discussions focused on the new hepatitis C medications. Two things really struck me about this.
Topics: Hepatitis C
Last week’s blog post discussed the dangerous precedent that exclusivity deals between drug manufacturers and payers set. Deals like the one Express Scripts and AbbVie’s signed for discounted rates on the new Hepatitis C drug, Viekira Pak. I argued that these deals emphasize the payer trend of focusing on immediate savings rather than overall outcomes, total cost of care and most importantly patient safety.
It’s becoming clear that my argument was right.
Hepatitis is a fancy word for liver inflammation. Sounds just somewhat serious, right?
Wrong, infections that cause Hepatitis can be a very grim business. In fact, they are responsible for one of the world’s largest healthcare burdens.
Hepatitis can be caused by different viral infections that are designated by the astonishingly creative nomenclature of A, B, C, D, and E. Hepatitis C (HCV) is what we will focus on today. ~200 million people carry this virus around inside them, including 3-4 million Americans. Ten times as many people are infected with HCV than HIV. It is the most common blood-borne viral infection in the world and is responsible for substantial amounts of morbidity and death.